^
Association details:
| Biomarker: | JAK2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | DT2216 (Bcl-xL degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4154 Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2-Mutant AML Post-MPN Models
Published date:
11/02/2023
Excerpt:
DT2216 as a single agent significantly reduced cell viability in JAK2-mut AML cell lines...These findings highlight the promising efficacy of DT2216 in JAK2-mut AML...
